Clinical trial · Interventional
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Sintilimab, Bevacizumab Plus Y-90 Selective Internal Radiation Therapy for Patients With Unresectable Intermediate-advanced Hepatocellular Carcinoma: a Prospective, Single-center, Single Arm Trial
NCT06397222CI-TRIAL-00076828recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma Non-resectable | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sin-Bev-SIRT | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sin-Bev-SIRT
- description
- Sintilimab, Bevacizumab plus SIRT
- interventionNames
- Drug: Sin-Bev-SIRT
Primary outcomes (1)
- measure
- Progression free survival (PFS) according to mRECIST
- timeFrame
- 3 years
- description
- The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.
Secondary outcomes (5)
- measure
- Progression free survival (PFS) according to RECIST 1.1
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Unresectable HCC (BCLC stage B/C or CNLC II/III) with diagnosis confirmed by histology/cytology or clinically * At least one measurable untreated lesion * Intrahepatic tumors can be treated with 1-2 sessions of SIRT * Child-Pugh score 5-7 * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 * Life expectancy of at least 3 months * Patients with active hepatitis B are allowed, but they need to receive antiviral treatment to achieve a HBV DNA\<10\^3 IU/mL * Patients with hepatitis C need to finish the anti-HCV treatment Exclusion Criteria: * tumor extent ≥70% liver occupation * Tumor thrombus involving main portal vein or both the first left and right branches of portal vein * Vena cava invasion * Central nervous system metastasis * Metastatic disease that involves major airways or blood vessels * Patients who previously received hepatic arterial infusion chemotherapy (HAIC), transarterial chemoembolization (TACE), transarterial embolization (TAE), radiotherapy, systemic therapy for HCC * History of organ and cell transplantation * Prior esophageal and/or gastric varices bleeding * Hepatic dysfunction, such as ascites, esophagogastric varices, hepatic encephalopathy * Evidence of portal hypertension with high risk of bleeding * Use of immunosuppressive medications within 4 weeks prior to the first dose of study treatment * Major surgical procedure or unhealed wound, ulcer, or fracture within 4 weeks prior to the first dose of study treatment * Any life-threatening bleeding event within the previous 3 months, including the need for blood transfusion, surgical or localized treatment, or ongoing drug therapy * Peripheral blood white blood cell count \<3×10\^9/L and platelet count \<50×10\^9/L * Prolonged prothrombin time \>4 seconds * Severe organ (heart, lung, kidney) dysfunction * History of other malignancies * Co-infection with hepatitis B and C viruses * Human immunodeficiency virus infection * Pregnant or lactating patients
References
Publications (0)
Data not yet available
No reference posted for this study.